ALXN - Alexion Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
118.60
-4.84 (-3.92%)
At close: 4:00PM EST

118.60 0.00 (0.00%)
After hours: 4:44PM EST

Stock chart is not supported by your current browser
Previous Close123.44
Open123.52
Bid118.00 x 800
Ask124.71 x 800
Day's Range118.32 - 123.54
52 Week Range102.10 - 140.77
Volume1,215,687
Avg. Volume1,551,384
Market Cap26.459B
Beta (3Y Monthly)1.08
PE Ratio (TTM)N/A
EPS (TTM)-0.45
Earnings DateFeb 6, 2019 - Feb 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est163.29
Trade prices are not sourced from all markets
  • AVEO Pharmaceuticals (AVEO) Q3 Earnings & Revenues Top Mark
    Zacks9 hours ago

    AVEO Pharmaceuticals (AVEO) Q3 Earnings & Revenues Top Mark

    AVEO Pharmaceuticals' (AVEO) loss is narrower than estimated in the third quarter. Also, the company???s revenues beat estimates.

  • How Analysts View Alexion Stock
    Market Realist3 days ago

    How Analysts View Alexion Stock

    In November 2018, of the total 18 analysts covering Alexion Pharmaceuticals (ALXN), 16 analysts have given the stock a “buy” or higher rating, and two analysts have given it a “hold” rating. The mean rating for Alexion Pharmaceuticals stock is 1.83 with a target price of $163.29, implying an upside potential of 28.4% over Alexion Pharmaceuticals’ closing price of $127.18 on November 10, 2018.

  • Analyzing Alexion Pharmaceuticals’ Dicerna Collaboration
    Market Realist3 days ago

    Analyzing Alexion Pharmaceuticals’ Dicerna Collaboration

    In October 2018, Alexion Pharmaceuticals (ALXN) entered a collaboration with Dicerna Pharmaceuticals that provides Alexion exclusive worldwide licenses and development and commercial rights to two molecules for complement-mediated diseases along with an exclusive option for other molecules for two additional targets within the complement pathway. Under the collaboration, Alexion will make an upfront payment of $37.0 million and could be required to pay up to ~$625.0 million in milestone payments and royalties on product sales.

  • See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.
    Markit3 days ago

    See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.

    Alexion Pharmaceuticals Inc NASDAQ/NGS:ALXN

  • How Alexion Pharmaceuticals’ Bottom Line Is Trending
    Market Realist4 days ago

    How Alexion Pharmaceuticals’ Bottom Line Is Trending

    Alexion Pharmaceuticals’ (ALXN) interest expense remained relatively flat at $24.6 million in the third quarter of 2018 as compared with $25.0 million in the year-ago period. Alexion Pharmaceuticals’ net income jumped from $78.0 million in the third quarter of 2017 to $330.9 million in the latest quarter, which translated into net earnings per share of $1.47 in the third quarter of 2018. Alexion’s recent major acquisitions include Wilson Therapeutics in May 2018 and Syntimmune in September 2018.

  • A Look at Alexion Pharmaceuticals’ Operational Performance
    Market Realist4 days ago

    A Look at Alexion Pharmaceuticals’ Operational Performance

    For fiscal 2018 and 2019, Alexion Pharmaceuticals’ gross margins are expected at 91.08% and 91.22%, respectively, as compared with gross margins of 91.95% for fiscal 2017. In comparison, fiscal 2018 gross margins for peers Abbott Laboratories (ABT), Amgen (AMGN), and Johnson & Johnson (JNJ) are expected at 59.29%, 85.73%, and 70.43%, respectively. Alexion Pharmaceuticals incurred selling, general, and administrative expenses of $258.7 million in the third quarter of 2018 as compared with $270.6 million in the third quarter of 2017.

  • How Alexion Is Positioned in November
    Market Realist4 days ago

    How Alexion Is Positioned in November

    Alexion Pharmaceuticals (ALXN), a global biopharmaceutical company, is a leader in complement inhibition and is focused on the therapeutic areas of hematology, nephrology, neurology, and metabolic disorders. Alexion has brought to market the only approved complement inhibitor for paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. Further, the company has two enzyme replacement therapies for hypophosphatasia and lysosomal acid lipase deficiency.

  • Analyzing Alexion Pharmaceuticals’ Product Performance
    Market Realist4 days ago

    Analyzing Alexion Pharmaceuticals’ Product Performance

    Alexion Pharmaceuticals’ (ALXN) key products on the market include Soliris, Strensiq, and Kanuma. Total Soliris sales increased from $755.4 million in the third quarter of 2017 to $888.0 million in the latest quarter. Its US sales increased from $307.6 million in the third quarter of 2017 to $404.5 million in the latest quarter. Its Europe sales increased from $248.4 million in the third quarter of 2017 to $262.1 million in the latest quarter.

  • Alexion Pharmaceuticals Dropped 19.4% in October, but the Business Remains Strong
    Motley Fool4 days ago

    Alexion Pharmaceuticals Dropped 19.4% in October, but the Business Remains Strong

    The large-cap biopharma experienced its worst month of 2018. Then it raised full-year 2018 financial guidance.

  • Business Wire5 days ago

    Alexion to Present at Credit Suisse’s 27th Annual Healthcare Conference

    Alexion Pharmaceuticals today announced that management will present at Credit Suisse’s 27th Annual Healthcare Conference in Scottsdale, AZ on Tuesday, November 13, 2018 at 10:00 a.m., ET.

  • Is Alexion Pharmaceuticals (ALXN) Stock Outpacing Its Medical Peers This Year?
    Zacks6 days ago

    Is Alexion Pharmaceuticals (ALXN) Stock Outpacing Its Medical Peers This Year?

    Is (ALXN) Outperforming Other Medical Stocks This Year?

  • Business Wire10 days ago

    Alexion Completes Acquisition of Syntimmune

    Alexion Pharmaceuticals, Inc. (ALXN) today announced that the previously announced acquisition of Syntimmune has been successfully completed. The acquisition adds to the company’s growing pipeline with the addition of clinical-stage SYNT001, a humanized monoclonal antibody that inhibits the interaction of neonatal Fc receptor (FcRn) with Immunoglobulin G (IgG) and IgG immune complexes with the potential to treat a number of rare IgG-mediated diseases.

  • GlobeNewswire11 days ago

    Report: Developing Opportunities within General Electric, Arch Capital Group, China Petroleum & Chemical, Alexion Pharmaceuticals, GAIN Capital, and Sony — Future Expectations, Projections Moving into 2018

    NEW YORK, Nov. 02, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • ACCESSWIRE11 days ago

    Today's Research Reports on Trending Tickers: Alexion Pharmaceuticals and OncoSec Medical

    NEW YORK, NY / ACCESSWIRE / November 2, 2018 / U.S. markets rallied on Thursday, with the S&P 500 Index logging its first 3-day win streak in six weeks, as trade concerns between the U.S. and China continued ...

  • Thomson Reuters StreetEvents11 days ago

    Edited Transcript of ALXN earnings conference call or presentation 24-Oct-18 12:00pm GMT

    Q3 2018 Alexion Pharmaceuticals Inc Earnings Call

  • Biotech ETFs in Focus on String of Q3 Earnings Beat
    Zacks11 days ago

    Biotech ETFs in Focus on String of Q3 Earnings Beat

    Biotech ETFs draw attention post impressive Q3 results.

  • Business Wire11 days ago

    Alexion Announces Upcoming Data Presentations at American Society of Hematology Annual Meeting

    Alexion Pharmaceuticals, Inc. (ALXN) today announced that nine abstracts from its complement research and development program have been accepted for presentation at the American Society of Hematology (ASH) Annual Meeting in San Diego, December 1 to 4, 2018. Key data will include both new analyses and previously announced results from the two Phase 3 studies of ALXN1210, the Company’s investigational long-acting C5 complement inhibitor, in patients with paroxysmal nocturnal hemoglobinuria (PNH), in addition to further data on Soliris® (eculizumab) for the treatment of PNH and atypical hemolytic uremic syndrome (aHUS).

  • Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q3, DRNA Soars on LLY Deal
    Zacks12 days ago

    Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q3, DRNA Soars on LLY Deal

    Impressive third-quarter results by most biotech bigwigs were the key highlights of the week. Most companies upped their guidance.

  • Alexion Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
    Zacks13 days ago

    Alexion Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

    Alexion Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

  • How Did Alexion Pharmaceuticals Fare in Q3 2018?
    Market Realist19 days ago

    How Did Alexion Pharmaceuticals Fare in Q3 2018?

    Alexion Pharmaceuticals (ALXN) released its third-quarter results on October 24. Boosted by the strong performance of Soliris and Strensiq, the company’s total revenues increased 20% from $859.1 million in the third quarter of 2017 to $1.03 billion in the third quarter. Alexion’s cost of sales decreased from $157.0 million in the third quarter of 2017 to $90.6 million in the third quarter.

  • Alexion Pharmaceuticals Inc (ALXN) Q3 2018 Earnings Conference Call Transcript
    Motley Fool19 days ago

    Alexion Pharmaceuticals Inc (ALXN) Q3 2018 Earnings Conference Call Transcript

    ALXN earnings call for the period ending September 30, 2018.

  • Investor's Business Daily19 days ago

    Big Cap 20 Biotech Stock Dives On Mixed Third-Quarter Revenue

    Alexion posted an "impressive" 54% operating margin in the third quarter, leading to a big beat on adjusted earnings, but shares slid Wednesday as revenue missed some estimates.

  • Alexion enters RNA gene-silencing field with $637M Dicerna deal
    American City Business Journals19 days ago

    Alexion enters RNA gene-silencing field with $637M Dicerna deal

    Newly Massachusetts-based biotech Alexion Pharmaceuticals became the latest company to enter the gene silencing drug field, signing a deal with Dicerna Pharmaceuticals worth upwards of $637 million.

  • The Wall Street Journal20 days ago

    [$$] Alexion 3Q Profit Up, Boosts Revenue Guidance

    The rare-disease drugmaker said third-quarter profit rose to $330.9 million, or $1.47 a share, from $78.0 million, or 35 cents a share, a year earlier.